Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olanzapine + risperidone + aripiprazole + quetiapine + amisulpride
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Intravenous
01
Overview
This is a combination of five atypical antipsychotic drugs: olanzapine, risperidone, aripiprazole, quetiapine, and amisulpride. Each drug acts primarily as an antagonist or partial agonist at dopamine D2 receptors and various serotonin receptors in the brain. These medications are individually approved for the treatment of schizophrenia and other psychiatric disorders such as bipolar disorder; some also have indications for depression or prevention of postoperative nausea and vomiting. The combination of multiple antipsychotics is not standard practice due to increased risk of side effects and limited evidence supporting superior efficacy over monotherapy; however, combinations may be used in treatment-resistant cases under specialist supervision[1][2][5]. All five agents are classified as second-generation (atypical) antipsychotics.
- Brand names
- Zyprexa (olanzapine)Risperdal (risperidone)Abilify (aripiprazole)Seroquel (quetiapine)Solian (amisulpride)Barhemsys (amisulpride)
02
Targets
DRD3 (Dopamine receptor D3)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on olanzapine + risperidone + aripiprazole + quetiapine + amisulpride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olanzapine + risperidone + aripiprazole + quetiapine + amisulpride.